Neoadjuvant Endocrine Therapy in Breast Cancer
A special issue of Current Oncology (ISSN 1718-7729). This special issue belongs to the section "Breast Cancer".
Deadline for manuscript submissions: 30 November 2026 | Viewed by 141
Special Issue Editor
Special Issue Information
Dear Colleagues,
Neoadjuvant endocrine therapy (NET) is an established treatment option for patients with hormone receptor-positive, HER2-negative breast cancer, particularly in postmenopausal women. NET aims to reduce tumor burden prior to surgery by inhibiting estrogen-driven proliferation through aromatase inhibitors or selective estrogen receptor modulators. Its use facilitates breast-conserving surgery in patients who might otherwise require mastectomy and provides an in vivo assessment of endocrine sensitivity. Biomarkers such as Ki67 and the Preoperative Endocrine Prognostic Index (PEPI) offer valuable prognostic information and help stratify patients according to their likelihood of long-term endocrine responsiveness. Compared with neoadjuvant chemotherapy, NET is generally better tolerated and associated with favorable toxicity profiles, making it especially relevant for patients with comorbidities or low-grade tumors. Overall, NET should be a key component of personalized treatment strategies, improving surgical outcomes and providing early biological insights that inform adjuvant therapy decisions.
Dr. Covadonga Martí
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Current Oncology is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- breast cancer
- neoadjuvant endocrine therapy
- hormone receptor–positive
- aromatase inhibitors
- ki67
- breast-conserving surgery
- endocrine responsiveness
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
